Business Context and Reporting Period
Company: CURIS, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2005
Business Overview: Curis is a therapeutic drug development company focused on modulating regulatory signaling pathways for tissue repair and regeneration. The company operates in a single segment: developmental biology products. Its lead product candidate, a topical therapy for basal cell carcinoma, is in Phase I clinical trials and is co-developed with Genentech, Inc.
Key Financial Metrics
| Metric (Six Months Ended June 30, 2005) | Amount ($) |
|---|---|
| Net Revenues | 987,911 |
| Gross Revenues | 5,866,413 |
| Contra-Revenues (Genentech Co-dev) | (4,878,502) |
| Net Loss | (9,787,901) |
| Net Loss Per Share (Basic & Diluted) | (0.20) |
| Cash and Cash Equivalents | 19,136,568 |
| Marketable Securities | 29,392,086 |
| Total Current Assets | 49,891,954 |
| Total Current Liabilities | 10,730,292 |
| Working Capital | 39,161,662 |
| Accumulated Deficit | (672,760,610) |
| Net Cash Used in Operating Activities | (3,715,159) |
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 50% to $988,000 for the six months ended June 30, 2005, compared to $1,976,000 in the prior year period. This decline was driven by $4.88 million in contra-revenues recorded to offset co-development costs paid to Genentech, despite a 197% increase in gross revenues to $5.87 million.
- Increased Loss: Net loss increased to $9.79 million from $8.34 million in the prior year period, primarily due to higher R&D spending and the contra-revenue accounting treatment.
- R&D Expenses: Research and development expenses increased 21% to $6.80 million, largely due to $1.47 million in spending on a new discovery research program funded by the Spinal Muscular Atrophy Foundation.
- Debt Structure: The company converted a $3.3 million convertible note from Elan Pharma International into common stock in January 2005. New debt obligations include a $2.25 million term note with Boston Private Bank & Trust Company.
- Sublease Loss: The company recorded a $500,000 charge in General and Administrative expenses due to the anticipated loss of subtenant income for its Cambridge facility.
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes existing capital resources ($48.5 million in cash and marketable securities) combined with contractually defined payments from collaborators (Genentech, Wyeth, SMA Foundation) will fund operations into mid-2007.
- Development Costs: The company expects to incur approximately $20 million in development expenses through Phase II clinical trials for its basal cell carcinoma candidate, with Phase II completion anticipated in mid-2007.
- Profitability: The company has never been profitable and does not expect to achieve profitability in the foreseeable future. It anticipates continuing to incur significant operating losses.
- Key Risks:
- Financing: Future funding beyond mid-2007 is dependent on collaboration success and the ability to raise additional equity or debt, which may be dilutive.
- Collaboration Dependence: 79% of gross revenue in the first half of 2005 was derived from three collaborators (Genentech, Wyeth, Ortho Biotech). Termination or failure of these partners would severely impact operations.
- Real Estate: Uncertainty regarding the ability to re-sublet 67% of its facility at favorable rates after the current subtenant vacates in December 2005.
- Accounting Changes: Implementation of SFAS No. 123(R) regarding stock-based compensation is expected in Q1 2006, which will materially impact reported results.
Investor Verification Checklist
- Contra-Revenue Impact: Verify the sustainability of net revenue given the accounting treatment (EITF 01-9) that offsets Genentech co-development costs against revenue, potentially resulting in zero net revenue until FDA approval.
- Cash Burn Rate: Confirm the timeline for additional financing needs, as the company projects funding only through mid-2007 despite a $672 million accumulated deficit.
- Sublease Liability: Assess the risk of the $500,000 recorded loss on the Cambridge facility sublease and the potential for additional costs if re-subletting fails.
- Stock-Based Compensation: Monitor the impact of the upcoming adoption of SFAS 123(R) in 2006, which will likely increase reported expenses significantly compared to current pro forma estimates.
- Debt Covenants: Review compliance with the working capital ratio covenant required by the Boston Private Bank & Trust Company note, as failure could trigger immediate repayment.